Sector News

Without tax reform, pharma M&A's still sluggish—but biotech's red hot

October 23, 2017
Life sciences

Back when the year began, the prospect of U.S. tax reform had pharma companies salivating for some M&A action. But with that reform still absent, drugmakers have put on the brakes instead.

Dealmaking in 2017 has so far seen a slowdown, tallying $207.6 billion across 1,040 deals in the pharma, medical and biotech sector, a new Mergermarket report (PDF) said. That’s a 9.9% dip in value and 106 fewer transactions compared with the same period last year.

The industry’s sluggish deal pace was particularly apparent last quarter; just $42.9 billion worth of deals came to fruition, the lowest quarterly value since the same period in 2014 and its $46.3 billion. And just one deal—Gilead’s $10.2 billion Kite buyout agreement, which will hand the Big Biotech newly approved CAR-T medication Yescarta—generated nearly 35% of the quarter’s dealmaking haul.

Make no mistake: It’s pharma that’s dragging down the overall category. Biotech, in fact, is red hot, partly in thanks to the Gilead deal. Overall, the biotech field has already surpassed all annual totals that Mergermarket had on file, and its records date back to 2001.

That’s not to say pharma M&A can’t turn around—especially if tax reform shows up. Deal enthusiast Pfizer, for one, has listed uncertainty around tax reform as a reason to sit tight for now. Some analysts have suggested it may have its eye on Bristol-Myers Squibb, though, and that company would certainly cost a pretty penny.

Pfizer’s also potentially looking to sell off its consumer health unit, and analysts have suggested that Endo turn to the M&A arena to ease its struggles. Alvogen’s private equity owners have also held talks with Shanghai Pharmaceuticals that could lead to a $4 billion sale.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).